These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 28392277)

  • 1. N-(Aroyl)-N-(arylmethyloxy)-α-alanines: Selective inhibitors of aldose reductase.
    Nencetti S; La Motta C; Rossello A; Sartini S; Nuti E; Ciccone L; Orlandini E
    Bioorg Med Chem; 2017 Jun; 25(12):3068-3076. PubMed ID: 28392277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addressing selectivity issues of aldose reductase 2 inhibitors for the management of diabetic complications.
    Kumar M; Choudhary S; Singh PK; Silakari O
    Future Med Chem; 2020 Jul; 12(14):1327-1358. PubMed ID: 32602375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coumarin-thiazole and -oxadiazole derivatives: Synthesis, bioactivity and docking studies for aldose/aldehyde reductase inhibitors.
    Ibrar A; Tehseen Y; Khan I; Hameed A; Saeed A; Furtmann N; Bajorath J; Iqbal J
    Bioorg Chem; 2016 Oct; 68():177-86. PubMed ID: 27544072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancing activity and selectivity in a series of pyrrol-1-yl-1-hydroxypyrazole-based aldose reductase inhibitors: The case of trifluoroacetylation.
    Papastavrou N; Chatzopoulou M; Ballekova J; Cappiello M; Moschini R; Balestri F; Patsilinakos A; Ragno R; Stefek M; Nicolaou I
    Eur J Med Chem; 2017 Apr; 130():328-335. PubMed ID: 28259841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and molecular modeling of novel non-sulfonylureas as hypoglycemic agents and selective ALR2 inhibitors.
    Salem MG; Aziz YMA; Elewa M; Elshihawy HA; Said MM
    Bioorg Med Chem; 2019 Aug; 27(15):3383-3389. PubMed ID: 31221611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benzoxazinone-thiosemicarbazones as antidiabetic leads via aldose reductase inhibition: Synthesis, biological screening and molecular docking study.
    Shehzad MT; Imran A; Njateng GSS; Hameed A; Islam M; Al-Rashida M; Uroos M; Asari A; Shafiq Z; Iqbal J
    Bioorg Chem; 2019 Jun; 87():857-866. PubMed ID: 30551808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis, molecular modeling, selective aldose reductase inhibition and hypoglycemic activity of novel meglitinides.
    Salem MG; Abdel Aziz YM; Elewa M; Nafie MS; Elshihawy HA; Said MM
    Bioorg Chem; 2021 Jun; 111():104909. PubMed ID: 33895603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From a dull enzyme to something else: facts and perspectives regarding aldose reductase.
    Del Corso A; Cappiello M; Mura U
    Curr Med Chem; 2008; 15(15):1452-61. PubMed ID: 18537622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aldose reductase inhibitors: 2013-present.
    Quattrini L; La Motta C
    Expert Opin Ther Pat; 2019 Mar; 29(3):199-213. PubMed ID: 30760060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring antidiabetic potential of adamantyl-thiosemicarbazones via aldose reductase (ALR2) inhibition.
    Shehzad MT; Hameed A; Al-Rashida M; Imran A; Uroos M; Asari A; Mohamad H; Islam M; Iftikhar S; Shafiq Z; Iqbal J
    Bioorg Chem; 2019 Nov; 92():103244. PubMed ID: 31541804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Substituted 2-thioxothiazolidin-4-one derivatives showed protective effects against diabetic cataract via inhibition of aldose reductase.
    Huang W; Zhang Y; Liang X; Yang L
    Arch Pharm (Weinheim); 2020 Jun; 353(6):e1900371. PubMed ID: 32237167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative structure-activity analysis of 5-arylidene-2,4-thiazolidinediones as aldose reductase inhibitors.
    Sambasivarao SV; Soni LK; Gupta AK; Hanumantharao P; Kaskhedikar SG
    Bioorg Med Chem Lett; 2006 Feb; 16(3):512-20. PubMed ID: 16297625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular modelling and synthesis of spiroimidazolidine-2,4-diones with dual activities as hypoglycemic agents and selective inhibitors of aldose reductase.
    Salem MG; Abdel Aziz YM; Elewa M; Elshihawy HA; Said MM
    Bioorg Chem; 2018 Sep; 79():131-144. PubMed ID: 29751319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis, characterization, hypoglycemic and aldose reductase inhibition activity of arylsulfonylspiro[fluorene-9,5'-imidazolidine]-2',4'-diones.
    Iqbal Z; Hameed S; Ali S; Tehseen Y; Shahid M; Iqbal J
    Eur J Med Chem; 2015 Jun; 98():127-38. PubMed ID: 26005026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dietary sources of aldose reductase inhibitors: prospects for alleviating diabetic complications.
    Saraswat M; Muthenna P; Suryanarayana P; Petrash JM; Reddy GB
    Asia Pac J Clin Nutr; 2008; 17(4):558-65. PubMed ID: 19114390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of aldose reductase inhibition and docking studies of 6'-nitro and 6',6''-dinitrorosmarinic acids.
    Koukoulitsa C; Bailly F; Pegklidou K; Demopoulos VJ; Cotelle P
    Eur J Med Chem; 2010 Apr; 45(4):1663-6. PubMed ID: 20071057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-carboxylic acid inhibitors of aldose reductase based on N-substituted thiazolidinedione derivatives.
    Mohd Siddique MU; Thakur A; Shilkar D; Yasmin S; Halakova D; Kovacikova L; Prnova MS; Stefek M; Acevedo O; Dasararaju G; Devadasan V; Mondal SK; Jayaprakash V
    Eur J Med Chem; 2021 Nov; 223():113630. PubMed ID: 34175538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The aldose reductase inhibitory capacity of Sorbus domestica fruit extracts depends on their phenolic content and may be useful for the control of diabetic complications.
    Termentzi A; Alexiou P; Demopoulos VJ; Kokkalou E
    Pharmazie; 2008 Sep; 63(9):693-6. PubMed ID: 18819524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of new inhibitors of aldose reductase from molecular docking and database screening.
    Rastelli G; Ferrari AM; Costantino L; Gamberini MC
    Bioorg Med Chem; 2002 May; 10(5):1437-50. PubMed ID: 11886806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploiting oxadiazole-sulfonamide hybrids as new structural leads to combat diabetic complications via aldose reductase inhibition.
    Javid N; Munir R; Chaudhry F; Imran A; Zaib S; Muzaffar A; Iqbal J
    Bioorg Chem; 2020 Jun; 99():103852. PubMed ID: 32325339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.